SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $11.64, up 5.34% on the session, giving a market capitalisation of $2.17B. On trailing twelve-month figures it carries a trailing P/E of -55.09, a net margin of 0.0%. Its beta of 2.49 implies it has historically moved more than the broad market.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc. is most often compared with the following Healthcare names: